Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.
Mark Warren, Tamás Oroszlán, Michael Lillestol, Andrzej Stankiewicz, Piotr Karaś, Christine Kosch, Victoria Cózar-León, Monika Łukaszewicz, Samer Nakhle, Douglas Denham, Diego Bellido, David Fitz-Patrick, Philip Raskin, Yehuda Handelsman, Elena A Christofides, Edward Franek, Priscilla Hollander, Fernando Ovalle, David Huffman, John Reed
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2024;30(9):810-816